TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Oncology

Hormone replacement therapy following treatment of gynaecological malignancies

Key Statistics

  • ~21,000 — UK women DX gynae malignancy, 2015
  • 30–40% — Present pre-/peri-menopausal
  • 5 — Cancer sites covered (endometrial, ovarian, cervical, vulval, vaginal)

Don't-miss facts

  1. ~21,000 UK women/year diagnosed with gynaecological malignancy (2015); 30–40% pre-/peri-menopausal at diagnosis

  2. Cancer treatment (surgery/chemo/radiotherapy) in younger women can cause an induced menopause

  3. HRT safety must be judged by cancer type, stage and grade – covers endometrial, ovarian, cervical, vulval, vaginal cancers

  4. Most UK units lack menopause specialist access; do not withhold HRT reflexively – know true contraindications

  5. Non-hormonal alternatives have a role where HRT is contraindicated or declined

  6. Caveat: these notes are abstract-level only – verify against full TOG article for site-specific evidence and regimens

Scope of article

Endometrial Ovarian Cervical Vulval Vaginal

Abbreviation Key

  • HRT — hormone replacement therapy
  • UK — United Kingdom
  • TOG — The Obstetrician & Gynaecologist could not be retrieved (Wiley institutional access unavailable); verify against the original TOG article for additional detail.

Source: Richardson A, Ayres J, Cust M, Phillips A. Hormone replacement therapy following treatment of gynaecological malignancies. The Obstetrician & Gynaecologist 2019;21:291–298. doi:10.1111/tog.12607

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free